Business Context and Reporting Period
This Form 8-K was filed by Integrity Applications, Inc. (not Glucotrack, Inc.) on March 14, 2017, reporting events occurring on March 8, 2017. The company, incorporated in Delaware with principal offices in Ashdod, Israel, entered into a Securities Purchase Agreement with accredited investors to issue preferred stock and warrants.
Key Financial Metrics and Transaction Details
- Gross Proceeds: $2,560,000 received from the sale of 2,560 Units.
- Instrument Structure: Each Unit consists of one share of Series C 5.5% Convertible Preferred Stock, a Series C-1 Warrant (exercise price $4.50), and a Series C-2 Warrant (exercise price $7.75).
- Conversion and Exercise Potential: The Preferred Stock is convertible into 568,890 shares of Common Stock. The Warrants are exercisable for an aggregate of 1,137,780 shares of Common Stock.
- Placement Agent Compensation: The company paid a 10% commission (cash and stock) plus a 3% expense allowance. Additionally, the agent received warrants to purchase 113,778 shares at $4.50 and 56,889 shares at $7.75.
Material Changes and Context
This transaction represents the ninth closing of an ongoing offering of Units. The terms of this issuance mirror those of eight prior closings disclosed in previous 8-K filings between April 2016 and January 2017. The filing does not provide comparative financial metrics such as revenue, profit, or cash flow for the period, as it is a current report focused on a specific financing event rather than a periodic financial statement.
Outlook, Risks, and Unusual Items
- Unregistered Sale: The Units were sold without registration under the Securities Act of 1933, relying on the Section 4(a)(2) exemption for sales to accredited investors without general solicitation.
- Dilution Risk: The issuance includes significant potential dilution through the conversion of preferred stock and the exercise of warrants, with the Placement Agent warrants including full ratchet anti-dilution protection.
- Registration Rights: A Registration Rights Agreement was executed, substantially identical to prior agreements, granting purchasers rights to register their securities.
Investor Verification Checklist
- Verify the total aggregate capital raised across all nine closings of this offering to assess total dilution impact.
- Confirm the current outstanding share count of Common Stock to calculate the percentage increase resulting from the 568,890 convertible shares and 1,137,780 warrant shares.
- Review the company's most recent 10-K or 10-Q to understand the cash burn rate and runway provided by the $2.56 million in gross proceeds.
- Examine the "full ratchet" anti-dilution provision in the Placement Agent warrants to understand potential future dilution scenarios if the stock price drops below $4.50.